Dermata Therapeutics Inc (DRMA) Stock Price, Quote & News

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 800 2543

Website: www.dermatarx.com

Address:

3525 Del Mar Heights Rd., Suite 332, San Diego, United States

kpasch8 Dec. 4 at 4:48 PM

$DRMA dilute diluted dilute

0 · Reply

_www_larval_com_ Dec. 4 at 4:47 PM

Look $DRMA has stumbled -10% lower to -20% (~191Kv) in the last few minutes, follow for more volatility.

0 · Reply

GTMStox Dec. 4 at 4:46 PM

$DRMA must be dilution. Garbage company

0 · Reply

Bubbasoup09 Dec. 4 at 12:27 AM

$DRMA it’s doing something

0 · Reply

AverageTraders Dec. 3 at 11:59 PM

Banked up $3.4K profits on that run! Thank you! Made my whole month! Make sure you FOLLOW @ICEMAN_ALERTS below, Great trader!! He calls them early before anyone else. Love adding before the runs✅ Adding some $AXGN $ZONE $DRMA $PLTR

0 · Reply

dbr_island Dec. 3 at 11:57 PM

🚨EPOW🚨is my next LIFE CHANGING ticket after $PLRZ $KALA $DRMA $KITT $SMX

0 · Reply

GTMStox Dec. 2 at 8:22 PM

$DRMA Do something already...

0 · Reply

CoralSharkie Nov. 26 at 12:37 AM

$DRMA Bounce could come on news/ volume float is tiny here.

0 · Reply

Idiotinvestur Nov. 24 at 8:51 PM

$DRMA more

0 · Reply

kshonstocks Nov. 24 at 5:44 PM

$DRMA off the bottom and through the 9 dma

0 · Reply

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Nov 14, 2025, 4:05 PM EST - 20 days ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 2, 2025, 8:00 AM EDT - 2 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Sep 17, 2025, 1:00 AM EDT - 2 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 16, 2025, 8:35 AM EDT - 2 months ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 10, 2025, 8:00 AM EDT - 3 months ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Aug 13, 2025, 5:00 PM EDT - 4 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 8, 2025, 8:00 AM EDT - 5 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

May 14, 2025, 9:00 AM EDT - 7 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 15, 2025, 8:30 AM EDT - 8 months ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Mar 27, 2025, 8:15 PM EDT - 9 months ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 10:21 AM EDT - 9 months ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 9:57 AM EDT - 9 months ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 8:00 AM EDT - 9 months ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 17, 2025, 4:16 PM EDT - 9 months ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 4, 2025, 8:03 AM EST - 9 months ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Feb 25, 2025, 7:58 AM EST - 10 months ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 29, 2025, 4:05 PM EST - 11 months ago

Dermata to Present on BioPub on January 31, 2025

Jan 28, 2025, 4:05 PM EST - 11 months ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 23, 2025, 4:15 PM EST - 11 months ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 11 months ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025, 8:00 AM EST - 11 months ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

May 17, 2024, 8:30 AM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 15, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Mar 27, 2024, 4:05 PM EDT - 1 year ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 9, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Aug 31, 2023, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Jun 27, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Jun 13, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 8, 2023, 9:00 AM EDT - 2 years ago

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

May 26, 2023, 4:00 PM EDT - 2 years ago

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

kpasch8 Dec. 4 at 4:48 PM

$DRMA dilute diluted dilute

0 · Reply

_www_larval_com_ Dec. 4 at 4:47 PM

Look $DRMA has stumbled -10% lower to -20% (~191Kv) in the last few minutes, follow for more volatility.

0 · Reply

GTMStox Dec. 4 at 4:46 PM

$DRMA must be dilution. Garbage company

0 · Reply

Bubbasoup09 Dec. 4 at 12:27 AM

$DRMA it’s doing something

0 · Reply

AverageTraders Dec. 3 at 11:59 PM

0 · Reply

dbr_island Dec. 3 at 11:57 PM

🚨EPOW🚨is my next LIFE CHANGING ticket after $PLRZ $KALA $DRMA $KITT $SMX

0 · Reply

GTMStox Dec. 2 at 8:22 PM

$DRMA Do something already...

0 · Reply

CoralSharkie Nov. 26 at 12:37 AM

$DRMA Bounce could come on news/ volume float is tiny here.

0 · Reply

Idiotinvestur Nov. 24 at 8:51 PM

$DRMA more

0 · Reply

kshonstocks Nov. 24 at 5:44 PM

$DRMA off the bottom and through the 9 dma

0 · Reply

Jtree123 Nov. 21 at 3:10 PM

$XPON $GRI $DRMA $GXAI current penny holds!

1 · Reply

Marketmoverjoe Nov. 19 at 11:40 PM

$DRMA funny when 100 shares moves the needle and it's all you. Lets move this buy 250 shares

0 · Reply

Marketmoverjoe Nov. 19 at 11:32 PM

$DRMA just bought some shares. this always takes a run annually. low float. limited shares.

0 · Reply

DonZulu Nov. 19 at 11:01 PM

$DRMA shorts are just eating the market to reset it things will change soon and they will all get wrecked

0 · Reply

Golibajje Nov. 19 at 10:06 PM

$INM what a trade for me $$$ 😀😀😀😀 moving to $DRMA now (low float.. with 900k shares! do not hold long term though.. lol)

0 · Reply

Miok Nov. 19 at 6:33 PM

$DRMA did they just increase the OS amount?!! wtf

0 · Reply

Golibajje Nov. 18 at 7:57 PM

$DRMA RIP

0 · Reply

DARKP00L Nov. 18 at 11:06 AM

$DRMA 06:05 on Nov. 18 2025 Dermata Therapeutics Terminated License Agreement With Villani Dated Mar 31, 2017, Citing Strategic Shift To OTC Skin Care; Villani Will Not Recieve Milestone, Other Payments #tradeideas

0 · Reply

GTMStox Nov. 17 at 8:38 PM

$DRMA Nasty work here

0 · Reply

d_risk Nov. 14 at 11:48 PM

$DRMA - Dermata Therapeutics, Inc. - 10Q - Updated Risk Factors DRMA flags major new risks tied to its shift from Rx to OTC, including regulatory hurdles that could delay launches, require costly reformulation, or restrict product claims, plus heightened threats from counterfeiting and distribution disruptions impacting sales and reputation. #Pharmaceuticals #DistributionDisruptions #CounterfeitingRisk #ProductReformulation #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/DRMA/10-Q/2025-11-14

0 · Reply

MagicalKeys Nov. 12 at 4:51 PM

Made huge profit on this guys call, +9k$ Gave @MomentumZeus a FOLLOW . insane trader lol. He called CMCT couple days ago and it just ran 100%+ Watching $AMD $OPEN $BBAI $DRMA xx

2 · Reply

GTMStox Nov. 12 at 12:09 AM

$DRMA soon....

0 · Reply

Market Cap	3.07M
Revenue (ttm)	0.00
Net Income (ttm)	-12.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	300,700
Avg Vol	170,044
Day's Range	N/A - N/A
Shares Out	1.03M
Stochastic %K	81%
Beta	0.53
Analysts	Strong Sell
Price Target	$10.00